Muscle-Invasive Bladder Cancer
Jul 14, 2026
Hengrui Pharma Encounters FDA Regulatory Hurdle for Camrelizumab–Rivoceranib; Kailera Therapeutics Announces Positive Results for HRS-7535/KAI-7535 Across Two Phase 3 Studies; Jemperli Underscores Durable Clinical Complete Responses in dMMR/MSI-H Rectal Cancer; FDA Approves PADCEV-Keytruda Combination for Neoadjuvant and Adjuvant Treatment of Muscle-Invasive Bladder Cancer; Sanofi’s Subcutaneous Sarclisa Escena Gains US Approval
Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab–Rivoceranib Combination in Advanced Liver Cancer Hengrui Pharma and Elevar Therapeutics have encountered another setback in their efforts to secure U.S. approval for the combination of camrelizumab and rivoceranib, as the FDA has issued a thir...
Read More...
Apr 21, 2026
Novo Nordisk Reports Positive Phase 3 Results for Etavopivat in Sickle Cell Disease; UCB to Buy Neurona Therapeutics; KEYTRUDA Regimens Secure FDA Priority Review in Muscle-Invasive Bladder Cancer; Savara Announces FDA Review Extension for Molgramostim in Autoimmune PAP; Terremoto Biosciences Completes $108 Million Series C Financing to Expand AKT1 Inhibitor Development
Novo Nordisk’s Etavopivat Meets Phase 3 Endpoints in Sickle Cell Disease Novo Nordisk announced topline findings from HIBISCUS, a pivotal Phase 3 study evaluating once-daily oral etavopivat in adults and adolescents living with Sickle Cell Disease. The trial met both co-primary endpoints, with etavopivat showing...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
